Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins

Abstract

The invention is concerned with pharmaceutical combination preparations containing erythropoietin preparations and one or more modified haemoglobins. The combination preparations are especially useful for the treatment of manifest anaemias.

1 . Pharmaceutical combination preparation comprising 
 a) individual administration forms of an erythropoietin preparation suitable for the individual dosing of the active substance in an amount of 3,000-7,000 U, and    b) 50-100 ml of one or more modified haemoglobins.    
     
     
         2 . Combination preparation according to  claim 1 , characterized in that it contains 3,000-7,000 U of an erythropoietin preparation and 80-100 ml of modified haemoglobin.  
     
     
         3 . Combination preparation according to  claim 1  or  2 , characterized in that it contains 5,000-7,000 U of an erythropoietin preparation and 80-100 ml of modified haemoglobin.  
     
     
         4 . Combination preparation according to any one of claims  1 - 3 , characterized in that it contains 6,000-7,000 U of an erythropoietin preparation and about 100 ml of modified haemoglobin.  
     
     
         5 . Combination preparation according to  claim 1 , characterized in that it contains 3,000-5,000 U of an erythropoietin preparation and 80-100 ml, preferably 85-95 ml, of modified haemoglobin.  
     
     
         6 . Combination preparation according to  claim 1  for the treatment of manifest anaemias.  
     
     
         7 . Combination preparation according to any one of  claims 1  to  4  for the treatment of manifest anaemias with iron utilization disorders.  
     
     
         8 . Combination preparation according to  claim 5  for the treatment of manifest anaemias without iron utilization disorders.  
     
     
         9 . Process for the production of pharmaceutical combination preparations according to  claims 1  to  8 , characterized by formulating 3,000-7,000 U of an erythropoietin preparation in the form of individual administration forms and 50-100 ml of modified haemoglobin together or separately from each another with pharmaceutically usual carriers or adjuvants and making the respective preparations available in the form of combination preparations.  
     
     
         10 . Use of erythropoietin preparations with 3,000-7,000 U of EPO and 50-100 ml of one or more modified haemoglobins for the production of a pharmaceutical combination preparation for the treatment of manifest anaemias.  
     
     
         11 . Use of erythropoietin preparations with 5,000-7,000 U of EPO and 80-100 ml of one or more modified haemoglobins for the production of a pharmaceutical combination preparation for the treatment of manifest anaemias with iron utilization disorders.  
     
     
         12 . Use of erythropoietin preparations with 3,000-5,000 U of EPO and 80-100 ml of one or more modified haemoglobins for the production of a pharmaceutical combination preparation for the treatment of manifest anaemias without iron utilization disorders.  
     
     
         13 . Pharmaceutical unit pack comprising 3,000-7,000 U of an erythropoietin preparation in individual administration forms and 50-100 ml of one or more modified haemoglobins as a single administration form in one container or as separate administration forms in separate containers.  
     
     
         14 . Unit pack according to  claim 13 , characterized in that in each case the erythropoietin preparation and the modified haemoglobin are present in separate administration forms in the form of solutions for injection or infusion purposes.